|
melanoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that (i) SMRT and Trip-1 mRNAs are expressed in many human neuroblastoma and melanoma cell lines in basal conditions, (ii) SMRT mRNA expression in human neuroblastoma cell line SK-N-BE(2) increases after 48 hours of incubation with 1 microM RA and RARs specific agonists, (iii) Trip-1 mRNA in the same cell line does not change during incubation with RA or selective synthetic agonists for RARs and RXR.
|
9169003 |
1997 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that (i) SMRT and Trip-1 mRNAs are expressed in many human neuroblastoma and melanoma cell lines in basal conditions, (ii) SMRT mRNA expression in human neuroblastoma cell line SK-N-BE(2) increases after 48 hours of incubation with 1 microM RA and RARs specific agonists, (iii) Trip-1 mRNA in the same cell line does not change during incubation with RA or selective synthetic agonists for RARs and RXR.
|
9169003 |
1997 |
|
Neuroectodermal Tumors
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the expression of the co-repressor (SMRT) and co-activator (Trip 1) for retinoid and thyroid-hormone receptors in several neuroectodermal tumour cell lines, and its modulation by all-trans-retinoic acid, as well as by synthetic agonists, for RAR alpha, RAR beta, RAR gamma and RXR.
|
9169003 |
1997 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that (i) SMRT and Trip-1 mRNAs are expressed in many human neuroblastoma and melanoma cell lines in basal conditions, (ii) SMRT mRNA expression in human neuroblastoma cell line SK-N-BE(2) increases after 48 hours of incubation with 1 microM RA and RARs specific agonists, (iii) Trip-1 mRNA in the same cell line does not change during incubation with RA or selective synthetic agonists for RARs and RXR.
|
9169003 |
1997 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate that (i) SMRT and Trip-1 mRNAs are expressed in many human neuroblastoma and melanoma cell lines in basal conditions, (ii) SMRT mRNA expression in human neuroblastoma cell line SK-N-BE(2) increases after 48 hours of incubation with 1 microM RA and RARs specific agonists, (iii) Trip-1 mRNA in the same cell line does not change during incubation with RA or selective synthetic agonists for RARs and RXR.
|
9169003 |
1997 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Molecular cloning and functional analysis of a novel cadmium-responsive proto-oncogene.
|
11830523 |
2002 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Nevertheless, the potential role of eIF3i in carcinogenesis is poorly understood.
|
16929481 |
2006 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Eukaryotic initiation factor 3 (eIF3) is involved in the initiation process of protein translation and overexpression of its subunit eukaryotic translation initiation factor i (eIF3i) has been observed in carcinomas.
|
16929481 |
2006 |
|
Malignant tumor of colon
|
0.300 |
Biomarker
|
disease |
CTD_human |
In this study, we investigated the expression of eIF3i in human colon cancers, tested its contribution to colon oncogenesis and determined the mechanism of eIF3i action in colon oncogenesis.
|
24056964 |
2014 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation.
|
24056964 |
2014 |
|
Colonic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation.
|
24056964 |
2014 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
By transfection of eIF3i shRNA, it was observed that reduced eIF3i expression suppressed the invasion of PC-3 cells in vitro.
|
25123845 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Here, we report that the eukaryotic translation initiation factor 3i (eIF3i) is required for VEGFA protein expression in both normal embryonic and tumorigenic angiogenesis. eIF3i is dynamically expressed in the early stages of zebrafish embryogenesis and in human hepatocellular carcinoma tissues. eIF3i homozygous mutant zebrafish embryos show severe angiogenesis defects and human hepatocellular cancer cells with depletion of eIF3i to induce less angiogenesis in tumor models.
|
25147179 |
2014 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The translation initiation factor eIF3i up-regulates vascular endothelial growth factor A, accelerates cell proliferation, and promotes angiogenesis in embryonic development and tumorigenesis.
|
25147179 |
2014 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we report that the eukaryotic translation initiation factor 3i (eIF3i) is required for VEGFA protein expression in both normal embryonic and tumorigenic angiogenesis. eIF3i is dynamically expressed in the early stages of zebrafish embryogenesis and in human hepatocellular carcinoma tissues. eIF3i homozygous mutant zebrafish embryos show severe angiogenesis defects and human hepatocellular cancer cells with depletion of eIF3i to induce less angiogenesis in tumor models.
|
25147179 |
2014 |
|
Childhood Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that the eukaryotic translation initiation factor 3i (eIF3i) is required for VEGFA protein expression in both normal embryonic and tumorigenic angiogenesis. eIF3i is dynamically expressed in the early stages of zebrafish embryogenesis and in human hepatocellular carcinoma tissues. eIF3i homozygous mutant zebrafish embryos show severe angiogenesis defects and human hepatocellular cancer cells with depletion of eIF3i to induce less angiogenesis in tumor models.
|
25147179 |
2014 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that the eukaryotic translation initiation factor 3i (eIF3i) is required for VEGFA protein expression in both normal embryonic and tumorigenic angiogenesis. eIF3i is dynamically expressed in the early stages of zebrafish embryogenesis and in human hepatocellular carcinoma tissues. eIF3i homozygous mutant zebrafish embryos show severe angiogenesis defects and human hepatocellular cancer cells with depletion of eIF3i to induce less angiogenesis in tumor models.
|
25147179 |
2014 |
|
Malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report that the eukaryotic translation initiation factor 3i (eIF3i) is required for VEGFA protein expression in both normal embryonic and tumorigenic angiogenesis. eIF3i is dynamically expressed in the early stages of zebrafish embryogenesis and in human hepatocellular carcinoma tissues. eIF3i homozygous mutant zebrafish embryos show severe angiogenesis defects and human hepatocellular cancer cells with depletion of eIF3i to induce less angiogenesis in tumor models.
|
25147179 |
2014 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These findings indicate that CLU is an independent predictive factor for prognosis of HCC and it facilitates metastasis through EIF3I/Akt/MMP13 signaling.
|
25609201 |
2015 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings indicate that CLU is an independent predictive factor for prognosis of HCC and it facilitates metastasis through EIF3I/Akt/MMP13 signaling.
|
25609201 |
2015 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Gene therapy model suggested that the growth and metastasis of cancer cells were suppressed by eIF3i shRNA.
|
28193911 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, our work established a selective translational regulatory mechanism during tumor induced angiogenesis and suggested that targeting eIF3i may be applicable for anticancer therapy.
|
28193911 |
2017 |
|
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We found that a key translational regulator, eIF3i, is highly expressed in endothelial cells during embryonic and tumor angiogenesis.
|
28193911 |
2017 |
|
Vesicular Stomatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
EIF3i affects vesicular stomatitis virus growth by interacting with matrix protein.
|
29173589 |
2017 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
|
31171919 |
2019 |